Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. Issue 2 (31st January 2019)

• Record Type: Journal Article
• Authors: Cubillos-Zapata, Carolina; Martínez-García, Miguel Ángel; Campos-Rodríguez, Francisco; Sánchez de la Torre, Manuel; Nagore, Eduardo; Martorell-Calatayud, Antonio; Hernández Blasco, Luis; Chiner Vives, Eusebi; Abad-Capa, Jorge; Montserrat, Josep María; Cabriada-Nuño, Valentín; Cano-Pumarega, Irene; Corral-Peñafiel, Jaime; Diaz-Cambriles, Trinidad; Mediano, Olga; Somoza-González, María; Dalmau-Arias, Joan; Almendros, Isaac; Farré, Ramón; López-Collazo, Eduardo; Gozal, David; García-Río, Francisco
• Is Part Of: European respiratory journal. Volume 53:Issue 2(2019)
• Publication Date: 2019-01-31
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01298-2018
• Languages: English
• ISSNs: 0903-1936

Abstract

Obstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness. In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness. sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%. Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects. In patients with cutaneous melanoma, severe OSA increases serum levels of sPD-L1, which are associated with several indices of tumour aggressiveness and are an independent risk factor of sentinel lymph node metastasis http://ow.ly/qAU030mC7xx